Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-722 PK Effect on Ethinyl Estradiol and Levonorgestrel
NCT07502417Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABBV-722, sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Cmax and 5 more. Started Mar 2026; status: completed.
02
Drugs
ABBV-722
Beyond the preview
Go deeper on NCT07502417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502417.